Literature DB >> 21479416

Immunohistochemical profile of various neurotransmitters, neurotrophins and MIB-1 in cholesteatomas of the petrous bone.

Marco Artico1, Elena Bronzetti, Vincenza Rita Lo Vasco, Brunella Ionta, Valentina Alicino, Anna D'Ambrosio, Giuseppe Magliulo.   

Abstract

Compared to the normal epidermal epithelium, cholesteatomas have altered growth properties characterized by the excessive growth of keratinocytes leading to mucosal destruction. Either congenital or acquired, these lesions, which grow in the middle ear space, the petrous apex or the mastoid of temporal bones, are mostly considered benign skin tumoral lesions. However, many questions remain concerning their pathophysiology. Numerous studies have been proposed to identify those cholesteatoma lesions at risk of recurrence, a possible event that may cause hearing loss. We examined patients with petrous apex or mastoid cholesteatoma in order to analyze the expression of various neurotransmitters, neurotrophins and their receptors and the Ki-67 antigen for identification of a possible relationship between clinical outcome and histopathological behaviour in terms of the proliferative activity of cholesteatomas. Expression of the analyzed molecules was studied using immunohistochemical methods in seven adult patients with petrous apex cholesteatoma who underwent surgical removal of the lesion. Our results, in accordance with published data, confirm that Molecular Immunology Borstel-1 (MIB-1) and certain neurotransmitters could be useful in the prognostic evaluation of the risk of recurrence of aggressive forms of cholesteatoma.

Entities:  

Year:  2008        PMID: 21479416

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  1 in total

1.  Reinke's edema: investigations on the role of MIB-1 and hepatocyte growth factor.

Authors:  M Artico; E Bronzetti; B Ionta; M Bruno; A Greco; G Ruoppolo; A De Virgilio; L Longo; M De Vincentiis
Journal:  Eur J Histochem       Date:  2010-07-08       Impact factor: 3.188

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.